Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

This retrospective cohort study was designed to provide further information on the association between BP parameters and VF ...

The European Commission (EC) has approved OPUVIZ 40 mg/mL solution for injection in a vial. OPUVIZ is a biosimilar referencing Eylea (aflibercept). The biosimilar has been developed and registered by ...

Gildeuretinol (ALK-001) received FDA Rare Pediatric Disease and Fast Track designations for Stargardt disease, highlighting ...

HelpMeSee’s Mazava Project trains general practitioners in Madagascar to perform cataract surgeries, addressing the country’s ...

HelpMeSee has partnered with new initiatives to address the global cataract blindness crisis, focusing on empowering women in ...

Sandoz's approval of Afqlir highlights their commitment to affordable, effective treatment options for retinal diseases.

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The ...

Livionex, recently announced a successful end-of-Phase 2 meeting with the FDA, supporting the advancement of C-KAD, a 2.6% EDTA ophthalmic solution, to a Phase 3 clinical study. In an interview with ...

The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Harrow announced that starting in January 2025, Vevye will be covered under key Medicare Part D formularies and across major ...